Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel, fast-acting, broad-spectrum antimicrobials to address infectious diseases and the growing threat of antibiotic-resistant bacterial strains. Headquartered in University Park, Florida, the company's mission is to improve patient outcomes by providing innovative solutions to critical unmet medical needs in infectious disease treatment.

The company's primary focus is on its proprietary Bisphosphocin® class of antimicrobial compounds. Its lead product candidate, Nu-3, is a topical gel currently in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). Beyond iDFU, Lakewood-Amedex is also exploring the potential of its Bisphosphocin® platform for other indications, including complicated urinary tract infections and pulmonary infections.

Lakewood-Amedex Biotherapeutics Inc. recently completed a direct listing on the Nasdaq Capital Market in April 2026, trading under the ticker symbol LABT. The company's leadership includes Kelvin Cooper, Ph.D., as Chief Executive Officer, and Doug Manion, M.D., as Chairman of the Board. Recent notable developments include positive data for its lead candidate Nu-3 and the expansion of its patent portfolio for Bisphosphocin® compounds.